Progesterone: Review of safety for clinical studies

被引:47
作者
Goletiani, Nathalie V.
Keith, Diana R.
Gorsky, Sara J.
机构
[1] McLean Hosp, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Cambridge, MA 02138 USA
关键词
progesterone; micronized progesterone; synthetic progesterone;
D O I
10.1037/1064-1297.15.5.427
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Progesterone is a steroid hormone that is important for reproductive function. Progesterone is used in a number of clinical applications and has been investigated as a possible novel approach for treatment of stimulant drug abuse. Extensive clinical studies have been conducted to examine the subjective and physiological effects of exogenous progesterone administration and to evaluate its side effects. This review summarizes the safety and side effects of acute and chronic administration of 3 progesterone formulations (synthetic, natural, and micronized natural), several routes of administration (oral, intramuscular, intravenous, intravaginal, intranasal, transdermal, and rectal), and dosing regimens. Synthetic progestins marketed as Provera, PremPro, and Cycrin are widely used but may produce a number of significant side effects, such as fatigue, fluid retention, lipid level alterations, dysphoria, hypercoagulant states, and increased androgenicity. Natural progesterones are reported to have milder adverse effects, depending on the route of administration. Micronized natural progesterone is available for oral administration, has better bioavailability and fewer side effects than natural progesterone, and is convenient to administer. Therefore, micronized natural progesterone appears to be a safe and effective alternative to synthetic and natural progesterone formulations for variety of clinical and research applications.
引用
收藏
页码:427 / 444
页数:18
相关论文
共 146 条
[51]  
Henzl MR, 2003, J REPROD MED, V48, P525
[52]  
Henzl MR, 2001, J REPROD MED, V46, P647
[53]   Midcycle administration of a progesterone synthesis inhibitor prevents ovulation in primates [J].
Hibbert, ML ;
Stouffer, RL ;
Wolf, DP ;
ZelinskiWooten, MB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1897-1901
[54]   Long-term use of the levonorgestrel-releasing intrauterine system [J].
Inki, Pirjo .
CONTRACEPTION, 2007, 75 (06) :S161-S166
[55]   Sex steroid hormone receptors in human thymoma [J].
Ishibashi, H ;
Suzuki, T ;
Suzuki, S ;
Moriya, T ;
Kaneko, C ;
Takizawa, T ;
Sunamori, M ;
Handa, M ;
Kondo, T ;
Sasano, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2309-2317
[56]   Future developments in hormonal contraception [J].
Johansson, EDB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (04) :S69-S71
[57]   Toxicology of progestogens of implantable contraceptives for women [J].
Jordan, A .
CONTRACEPTION, 2002, 65 (01) :3-8
[58]  
KIMZEY LM, 1991, FERTIL STERIL, V56, P995
[59]   Synthetic progestins used in HRT have different glucocorticoid agonist properties [J].
Koubovec, D ;
Ronacher, K ;
Stubsrud, E ;
Louw, A ;
Hapgood, JP .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2005, 242 (1-2) :23-32
[60]   Comparative pharmacology of newer progestogens [J].
Kuhl, H .
DRUGS, 1996, 51 (02) :188-215